Alembic Pharmaceuticals has informed that Aleor Dermaceuticals (Aleor), a 60:40 Joint Venture between the company and Orbicular Pharmaceutical Technologies (Orbicular), has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at Aleor's Formulation Facility at Karakhadi, Gujarat, India during the period from 4th February, 2019 to 8th February, 2019.
The above information is a part of company’s filings submitted to BSE.
